Stimulation of anti-tumor immunity using dendritic cell/tumor fusions and anti CD3/CD28

被引：0
|
作者：
Rosenblatt, J.
Wu, Z.
Lenahan, C.
Vasir, B.
Bisonette, A.
Kufie, D.
Avigan, D.
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2007年 / 13卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2006.12.192
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
188
引用
收藏
页码：69 / 70
页数：2
相关论文
共 50 条
  • [31] TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
    Yeo, Jinah
    Ko, Minkyung
    Lee, Dong-Hee
    Park, Yoon
    Jin, Hyung-seung
    PHARMACEUTICALS, 2021, 14 (03) : 1 - 20
  • [32] Engineered variant domain fusion proteins provide checkpoint inhibition and tumor antigen dependent CD28 costimulation resulting in potent anti-tumor immunity.
    Levin, Steven D.
    Maurer, Mark F.
    Gudgeon, Chelsea
    Chandrasekaran, Siddarth
    Ardourel, Daniel
    Demonte, Daniel
    Kuijper, Joseph
    Wolfson, Martin
    Garrett, Logan
    Kleist, Kayla N.
    Mudri, Sherri
    Nguyen, Hieu
    Seaberg, Michelle
    Wang, Rachel
    Yang, Jing
    Lewis, Katherine E.
    Dillon, Stacey R.
    Rixon, Mark
    Peng, Stanford L.
    CANCER RESEARCH, 2021, 81 (13)
  • [33] Targeting CD4+FOXP3+Tregs to enhance anti-tumor immunity
    Akimova, Tatiana
    Wang, Liqing
    Bartosh, Zhanna
    Eruslanov, Evgeniy
    Albelda, Steven
    Singhal, Sunil
    Aishwarya, Veenu
    Hancock, Wayne W.
    CANCER RESEARCH, 2024, 84 (06)
  • [34] Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: Correlation with decreased CD28 expression
    Roos, MTL
    Miedema, F
    Meinesz, AAP
    DeLeeuw, NASM
    Pakker, NG
    Lange, JMA
    Coutinho, RA
    Schellekens, PTA
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 105 (03): : 409 - 415
  • [35] The role of dendritic cells in cancer and anti-tumor immunity
    Marciscano, Ariel E.
    Anandasabapathy, Niroshana
    SEMINARS IN IMMUNOLOGY, 2021, 52
  • [36] Modification of anti-tumor immunity by tolerogenic dendritic cells
    Chen, Liying
    Hasni, Mohammad Sharif
    Jondal, Mikael
    Yakimchuk, Konstantin
    AUTOIMMUNITY, 2017, 50 (06) : 370 - 376
  • [37] CD3 × CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation
    An Willems
    Steve Schoonooghe
    Dominique Eeckhout
    Geert De Jaeger
    Johan Grooten
    Nico Mertens
    Cancer Immunology, Immunotherapy, 2005, 54 : 1059 - 1071
  • [38] Anti-tumor effects of dendritic and tumor cell fusions are not dependent on expression of MHC class I and II by dendritic cells
    Takagi, Y
    Kikuchi, T
    Niimura, M
    Ohno, T
    CANCER LETTERS, 2004, 213 (01) : 49 - 55
  • [39] Induction of anti-tumor immunity by anti-tumor monoclonal antibodies
    Dhodapkar, Madhav V.
    JOURNAL OF IMMUNOTHERAPY, 2006, 29 (06) : 635 - 635
  • [40] Caspase 3 may participate in the anti-tumor immunity of dendritic cells
    Liu, Jinqiang
    Wang, Fei
    Yin, Dandan
    Zhang, Hongwei
    Feng, Fan
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 511 (02) : 447 - 453
12345